Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : iPSC-derived Therapy
Therapeutic Area : Ophthalmology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Eyestem to Begin Human Trials for its Pioneering Dry AMD Treatment
Details : Eyecyte RPE, is a lost or damaged retinal pigment epithelium cells replacement therapy is being investigated for the treatment geographic atrophy arising from dry age-related macular degeneration
Brand Name : Eyecyte-RPE
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
April 02, 2024
Lead Product(s) : iPSC-derived Therapy
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?